KIR2DL3

KIR2DL3 Informations sur la molécule

Nom anglais	Killer cell immunoglobulin-like receptor 2DL3	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	1	Alias de la cible	P58.2 MHC Class-I Specific NK Receptor，MHC Class I NK Cell Receptor，CD158b2 Antigen，KIR-K7b，KIR-K7c，KIR2DS5，CD158b，KIR2DL，NKAT2A，NKAT2B，GL183，NKAT，P58，Receptors， KIR2DL3，Cl-6，Killer Cell Immunoglobulin-Like Receptor Two Domains Long Cytoplasmic Tail 3，Natural Killer Cell Inhibitory Receptor KIR2DL3，Natural Killer Associated Transcript 2，p58.2 MHC class-I-specific NK receptor，Natural killer-associated transcript 2，NKAT-2，NKAT2，p58 natural killer cell receptor clone CL-6，Killer inhibitory receptor cl 2-3，CD158b2，Killer cell immunoglobulin-like receptor 2DL3，KIR2DL3，Killer Cell Immunoglobulin Like Receptor， Two Ig Domains And Long Cytoplasmic Tail 3，CD158 Antigen-Like Family Member B2，P58 NK Receptor CL-6，KIR-023GB，KIRCL23，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Short Cytoplasmic Tail， 5，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Long Cytoplasmic Tail， 3
Phase de R&D la plus avancée	Phase 2 Clinical

Nom anglais	Killer cell immunoglobulin-like receptor 2DL3
Alias de la cible	P58.2 MHC Class-I Specific NK Receptor，MHC Class I NK Cell Receptor，CD158b2 Antigen，KIR-K7b，KIR-K7c，KIR2DS5，CD158b，KIR2DL，NKAT2A，NKAT2B，GL183，NKAT，P58，Receptors， KIR2DL3，Cl-6，Killer Cell Immunoglobulin-Like Receptor Two Domains Long Cytoplasmic Tail 3，Natural Killer Cell Inhibitory Receptor KIR2DL3，Natural Killer Associated Transcript 2，p58.2 MHC class-I-specific NK receptor，Natural killer-associated transcript 2，NKAT-2，NKAT2，p58 natural killer cell receptor clone CL-6，Killer inhibitory receptor cl 2-3，CD158b2，Killer cell immunoglobulin-like receptor 2DL3，KIR2DL3，Killer Cell Immunoglobulin Like Receptor， Two Ig Domains And Long Cytoplasmic Tail 3，CD158 Antigen-Like Family Member B2，P58 NK Receptor CL-6，KIR-023GB，KIRCL23，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Short Cytoplasmic Tail， 5，Killer Cell Immunoglobulin-Like Receptor， Two Domains， Long Cytoplasmic Tail， 3
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	1
Phase de R&D la plus avancée	Phase 2 Clinical

KIR2DL3 Liste de produits

Attribut
Protein (1)
Bibliothèque de produits
En ligne (1)
Espèces
Human (1)
Étiquette
Fc Tag (1)
Marqueur
Unconjugated (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
KI3-H5258	Human	HEK293	Human KIR2DL3 / CD158b2 / NKAT-2 Protein, Fc Tag (MALS verified)				Ajouter au panier

Quantité totale1

KIR2DL3Contexte de la molécule

Killer cell immunoglobulin-like receptor 2DL3 (KIR2DL3) is also known as CD158 antigen-like family member B2, KIR-023GB, Killer inhibitory receptor cl 2-3, MHC class I NK cell receptor, NKAT2a, NKAT2b, Natural killer-associated transcript 2, p58 natural killer cell receptor clone CL-6, p58.2 MHC class-I-specific NK receptor, CD158b2 and KIR2DL3, which is a single-pass type I membrane protein and belongs to the immunoglobulin superfamily.KIR2DL3 is a receptor on natural killer (NK) cells for HLA-C alleles (HLA-Cw1, HLA-Cw3 and HLA-Cw7). KIR2DL3 can inhibit the activity of NK cells thus preventing cell lysis.

KIR2DL3Alias de la molécule

CD158b2

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Lirilumab	IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015	Phase 2 Clinical	Novo Nordisk A/S	Bone Marrow Neoplasms; Hodgkin Disease; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Smoldering Multiple Myeloma; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms	Details